Irodalom:
1. Pennathur A, Luketich JD, Landreneau RJ, Ward J.: Long-term results of a phase II trial of neoadjuvant
chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac
Surg. 2008 Jun;85(6):1930-6; discussion 1936-7.
2. Ku GY, Ilson DH.: Multimodality therapy for the curative treatment of cancer of the esophagus and
gastroesophageal junction. Expert Rev Anticancer Ther. 2008 Dec;8(12):1953-64.
3. Ku GY, Ilson DH.: Preoperative therapy in esophageal cancer. Clin Adv Hematol Oncol. 2008
May;6(5):371-9.
4. van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW,
van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC,
Offerhaus GJ, van der Gaast A.: Neoadjuvant chemoradiation followed by surgery versus surgery
alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC
Surg. 2008 Nov 26;8:21.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 81
82 Gastro Update 2009
5. Nakamura T, Ota M, Narumiya K, Sato T, Ohki T, Yamamoto M, Mitsuhashi N.: Multimodal treatment
for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008
Sep;15(9):2451-7. Epub 2008 Jul.
6. Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D,
Willett CG.: Phase II randomized trial of two nonoperative regimens of induction chemotherapy
followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin
Oncol. 2008 Oct 1;26(28):4551-6. Epub 2008 Jun 23. Links.
7. Chen F, Sato K, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Date H.: Pulmonary resection for
metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg. 2008 Oct;7(5):809-12. Epub
2008 Jun 13.
8. Shiono S, Kawamura M, Sato T, Nakagawa K, Nakajima J, Yoshino I, Ikeda N, Horio H, Akiyama H,
Kobayashi K; Metastatic Lung Tumor Study Group of Japan.: Disease-free interval length correlates to
prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol.
2008 Sep;3(9):1046-9.
9. Veuillez V, Rougier P, Seitz JF.: The multidisciplinary management of gastrointestinal cancer. Multimodal
treatment of oesophageal cancer. Best Pract Res Clin Gastroenterol. 2007;21(6):947-63.
10. Ekman S, Dreilich M, Lennartsson J, Wallner B, Brattström D, Sundbom M, Bergqvist M.: Esophageal
cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther. 2008 Sep;8(9):1433-48.
11. Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C.: Pilot study of
gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical
response. Am J Clin Oncol. 2008 Aug;31(4):329-34.
12. Boone J, Ten Kate FJ, Offerhaus GJ, van Diest PJ, Rinkes IH, van Hillegersberg R: mTOR in squamous
cell carcinoma of the oesophagus: a potential target for molecular therapy? J Clin Pathol. 2008
Aug;61(8):909-13. Epub 2008 May 12.
13. Langer R, Ott K, Specht K, Becker K, Lordick F, Burian M, Herrmann K, Schrattenholz A, Cahill MA,
Schwaiger M, Hofler H, Wester HJ: Protein expression profiling in esophageal adenocarcinoma patients
indicates association of heat-shock protein 27 expression and chemotherapy response. Clin Cancer Res.
2008 Dec 15;14(24):8279-87. Links.
14. Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H.: Expression and clinical significance of glucose
regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus.
BMC Cancer. 2008 Mar 10;8:70.
15. Rades D, Golke H, Schild SE, Kilic E.: Impact of VEGF and VEGF receptor 1 (FLT1) expression on
the prognosis of stage III esophageal cancer patients after radiochemotherapy. Strahlenther Onkol. 2008
Aug;184(8):416-20.
16. Rades D, Golke H, Schild SE, Kilic E.: The impact of tumor expression of erythropoietin receptors and
erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation. Int J
Radiat Oncol Biol Phys. 2008 May 1;71(1):152-9. Epub 2007 Oct 29.
17. Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K,
Peschel C, Siewert JR, Molls M, Lordick F.: Neoadjuvant continuous infusion of weekly 5-fluorouracil
and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous
cell carcinoma: results of a phase I/II trial. Br J Cancer. 2008 Oct 7;99(7):1020-6. Epub 2008 Sep 16.
18. Conroy T, Viret F, François E, Seitz JF, Boige V, Ducreux M, Ychou M, Metges JP, Giovannini M,
Yataghene Y, Peiffert D.: Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent
radiotherapy for oesophageal cancer. Br J Cancer. 2008 Nov 4;99(9):1395-401. Epub 2008 Oct 7.
19. Koussis H, Scola A, Bergamo F, Tonello S, Basso U, Karahontzitis P, Chiarion-Sileni V, Pasetto L, Ruol A,
Loreggian L, Lora O, Bottin R, Marioni G, Donach M, Jirillo A.: Neoadjuvant carboplatin and vinorelbine
Gastro 2009.qxd 5/9/2009 1:41 PM Page 82
A nyelõcsõ 83
followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell
carcinoma: a phase II study in elderly patients or patients with poor performance status. Anticancer
Res. 2008 Mar-Apr;28(2B):1383-8.
20. Triboulet JP., Mariette C.: Oesophageal cancer: what’s new during the last ten years? Bull.Cancer,2008
Apr; 95 (4)…425-31.
21. Tepper J., Krasna MJ., Niedzwiecki D.,Hollis D., Reed CE., Godberg L., Kiel K., Mayer R.: Phase III.
trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with
surgery alone for esophageal cancer: CALGB 9781. J.Clin.Oncol.2008 nov.1:26 (31):5133-4.
22. Borghesi S., Hawkins MA., Tait D.,: Oesophagectomia after definitiv chemoradiation in patients with
locally advanced oesophageal cancer. Clin.Oncol.2008. Apr. 20(3),221-6.
23. Yano T.,Muto M., Hattori S., Minashi K., Onozawa M., Yoshidaq S.,: Long-term results of salvage
endoscopic mucosal resection in patients with localfailure after definitiv chemoradiotherapy for
oesophageal squamous cell carcinoma. Endoscopy 2008. Se;40(9): 717-21.
24. Tachimori Y.,Kanmori N., Hokumura N., Kato H.: Salvage esophagectomy after high-dose chemoradiotherapy
for esophageal squamous cell carcinoma. J.Thoraci Cardiovasc. Surg. 2009.Jan;137(1):49-54.
25. Higuchi K., Kouzumi W., Tanaba S., Sasaki T., Hyakawa K.: A phase I. trial of definitiv chemoradiotherapy
with docetaxel, cisplatin, and 5 FU (DCF-R) for advanced esophageal carcinoma: Kitasato digestive
disease and oncology trial 0501. Radiother. Oncol. 2008.Jun. 87(3);398-404.
26. Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y,
Hatazawa J, Monden M.: Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission
tomography as a significant predictor of survival after subsequent surgery in multimodality treatment
for patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg.
2008 Jul;136(1):205-12, 212.
27. Zenda S, Hironaka S, Boku N, Yamazaki K, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Nishimura T.:
Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node
esophageal cancer. Dis Esophagus. 2008;21(3):195-200.
28. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA.: Significance of
thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma
of the esophagus and gastroesophageal junction. Dis Esophagus. 2008;21(7):575-81. Epub 2008 May 2.
29. van Meerten E, van der Gaast A, Looman CW, Tilanus HW, Muller K, Essink-Bot ML.: Quality of life
during neoadjuvant treatment and after surgery for resectable esophageal carcinoma. Int J Radiat Oncol
Biol Phys. 2008 May 1;71(1):160-6. Epub 2007 Dec 31.
